PF-06826647 Size:100mg solid The subcutaneous tumor growth of

The subcutaneous tumor growth of both T24 and HeLa cell xenografts treated with PAI-039 is markedly reduced compared with untreated controls

resulting in the proteasomal degradation of oncogenic client proteins

injections of 40 mg/kg/day canertinib (Fig

After treatment with U0126

All LGK974-sensitive pancreatic cancer cell lines carried inactivating mutations of RNF43

PF-06826647 Size:100mg solid The subcutaneous tumor growth ofPF 06826647 (Tyk2 IN 8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF 06826647 (Tyk2 IN 8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF 06826647 (Tyk2 IN 8, compound 10) is used in the treatment of psoriasis (PSO). Product information CAS Number: 2127109 84 4 Molecular Weight: 383. 41